Evidence map›Paper›PMID 34503133›Full record

ArticleCancers2021

Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy.

Guillemette Fouquet, Myriam Wartski, Amina Dechmi, Lise Willems, Bénédicte Deau-Fischer, Patricia Franchi, Justine Descroocq, Paul Deschamps, Estelle Blanc-Autran, Jérôme Clerc and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  2. Review
  3. Article
  4. Prognostic value ofAnnals of hematology · 2024
    Article
  5. Article
  6. Review
  7. New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Guillemette FouquetAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Myriam WartskiAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France.
Amina DechmiAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France.
Lise WillemsAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Bénédicte Deau-FischerAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Patricia FranchiAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Justine DescroocqAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Paul DeschampsAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Estelle Blanc-AutranHôpital Marie Lannelongue, Service de Médecine Nucléaire, 92350 Le Plessis-Robinson, France.
Jérôme ClercAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France.
Didier BouscaryAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Sylvain BarreauAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service D'hémato-Biologie, Hôpital Cochin, 75014 Paris, France.ORCID 0000-0002-5566-7369
Nicolas ChapuisAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service D'hémato-Biologie, Hôpital Cochin, 75014 Paris, France.
Marguerite VignonAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, 75014 Paris, France.
Anne-Ségolène CottereauAssistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France.
Université Paris Cité · FRHôpital Marie Lannelongue · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs,

Indexed as

anti-CD38FDG-PET/CTfocal bone lesionimmunotherapymyelomaprognostic factor

Identifiers

PMID34503133
PMCPMC8431719
OpenAlexW3197154784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.